![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TSEN34 |
Gene summary for TSEN34 |
![]() |
Gene information | Species | Human | Gene symbol | TSEN34 | Gene ID | 79042 |
Gene name | tRNA splicing endonuclease subunit 34 | |
Gene Alias | LENG5 | |
Cytomap | 19q13.42 | |
Gene Type | protein-coding | GO ID | GO:0000379 | UniProtAcc | A0A024R4N9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79042 | TSEN34 | LN38 | Human | Oral cavity | OSCC | 9.38e-05 | 1.14e+00 | 0.168 |
79042 | TSEN34 | LN46 | Human | Oral cavity | OSCC | 2.77e-40 | 1.53e+00 | 0.1666 |
79042 | TSEN34 | LP15 | Human | Oral cavity | LP | 1.70e-11 | 1.72e+00 | 0.2174 |
79042 | TSEN34 | LP17 | Human | Oral cavity | LP | 8.92e-05 | 9.10e-01 | 0.2349 |
79042 | TSEN34 | SYSMH1 | Human | Oral cavity | OSCC | 3.92e-13 | 3.91e-01 | 0.1127 |
79042 | TSEN34 | SYSMH2 | Human | Oral cavity | OSCC | 3.73e-29 | 8.97e-01 | 0.2326 |
79042 | TSEN34 | SYSMH3 | Human | Oral cavity | OSCC | 3.45e-36 | 1.14e+00 | 0.2442 |
79042 | TSEN34 | SYSMH4 | Human | Oral cavity | OSCC | 4.06e-08 | 2.82e-01 | 0.1226 |
79042 | TSEN34 | SYSMH5 | Human | Oral cavity | OSCC | 3.42e-04 | 2.13e-01 | 0.0647 |
79042 | TSEN34 | SYSMH6 | Human | Oral cavity | OSCC | 1.16e-10 | 4.62e-01 | 0.1275 |
79042 | TSEN34 | P4_S8_cSCC | Human | Skin | cSCC | 5.85e-05 | 1.48e-01 | -0.3095 |
79042 | TSEN34 | P5_S10_cSCC | Human | Skin | cSCC | 1.79e-11 | 1.54e-01 | -0.299 |
79042 | TSEN34 | P1_cSCC | Human | Skin | cSCC | 3.95e-32 | 1.20e+00 | 0.0292 |
79042 | TSEN34 | P2_cSCC | Human | Skin | cSCC | 1.76e-31 | 9.26e-01 | -0.024 |
79042 | TSEN34 | P4_cSCC | Human | Skin | cSCC | 9.18e-34 | 1.02e+00 | -0.00290000000000005 |
79042 | TSEN34 | P10_cSCC | Human | Skin | cSCC | 4.15e-26 | 9.48e-01 | 0.1017 |
79042 | TSEN34 | cSCC_p8 | Human | Skin | cSCC | 4.48e-13 | 1.43e-01 | -0.1971 |
79042 | TSEN34 | cSCC_p9 | Human | Skin | cSCC | 1.54e-06 | 1.73e-01 | -0.1991 |
79042 | TSEN34 | male-WTA | Human | Thyroid | PTC | 3.39e-42 | 4.09e-01 | 0.1037 |
79042 | TSEN34 | PTC01 | Human | Thyroid | PTC | 4.81e-17 | 4.47e-01 | 0.1899 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00344705 | Breast | Precancer | ncRNA processing | 42/1080 | 395/18723 | 9.91e-05 | 1.83e-03 | 42 |
GO:00346604 | Breast | Precancer | ncRNA metabolic process | 45/1080 | 485/18723 | 1.15e-03 | 1.26e-02 | 45 |
GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
GO:000838024 | Breast | DCIS | RNA splicing | 73/1390 | 434/18723 | 3.05e-11 | 5.08e-09 | 73 |
GO:003447011 | Breast | DCIS | ncRNA processing | 44/1390 | 395/18723 | 4.56e-03 | 3.49e-02 | 44 |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:00083801 | Colorectum | SER | RNA splicing | 123/2897 | 434/18723 | 3.84e-12 | 8.41e-10 | 123 |
GO:00083802 | Colorectum | MSS | RNA splicing | 159/3467 | 434/18723 | 1.75e-19 | 1.22e-16 | 159 |
GO:00083803 | Colorectum | MSI-H | RNA splicing | 82/1319 | 434/18723 | 1.22e-16 | 4.53e-14 | 82 |
GO:0034470 | Colorectum | MSI-H | ncRNA processing | 48/1319 | 395/18723 | 1.54e-04 | 4.47e-03 | 48 |
GO:0034660 | Colorectum | MSI-H | ncRNA metabolic process | 53/1319 | 485/18723 | 9.66e-04 | 1.68e-02 | 53 |
GO:000838026 | Esophagus | HGIN | RNA splicing | 160/2587 | 434/18723 | 3.74e-34 | 1.12e-30 | 160 |
GO:003447010 | Esophagus | HGIN | ncRNA processing | 97/2587 | 395/18723 | 5.92e-09 | 3.90e-07 | 97 |
GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
GO:00003942 | Esophagus | HGIN | RNA splicing, via endonucleolytic cleavage and ligation | 6/2587 | 11/18723 | 1.71e-03 | 1.86e-02 | 6 |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TSEN34 | SNV | Missense_Mutation | c.282N>T | p.Glu94Asp | p.E94D | protein_coding | tolerated(0.08) | benign(0.073) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TSEN34 | SNV | Missense_Mutation | novel | c.563N>C | p.Val188Ala | p.V188A | protein_coding | deleterious(0) | possibly_damaging(0.686) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TSEN34 | SNV | Missense_Mutation | rs775204637 | c.476N>T | p.Ser159Leu | p.S159L | protein_coding | tolerated(0.18) | benign(0.005) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TSEN34 | SNV | Missense_Mutation | rs778367406 | c.867G>C | p.Lys289Asn | p.K289N | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
TSEN34 | SNV | Missense_Mutation | rs374974634 | c.280N>A | p.Glu94Lys | p.E94K | protein_coding | deleterious(0.01) | benign(0.145) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
TSEN34 | SNV | Missense_Mutation | c.248G>T | p.Ser83Ile | p.S83I | protein_coding | tolerated(0.1) | benign(0.142) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
TSEN34 | SNV | Missense_Mutation | c.370G>A | p.Ala124Thr | p.A124T | protein_coding | deleterious(0.02) | possibly_damaging(0.89) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TSEN34 | SNV | Missense_Mutation | novel | c.412T>G | p.Ser138Ala | p.S138A | protein_coding | tolerated(0.62) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
TSEN34 | SNV | Missense_Mutation | rs778884462 | c.503C>T | p.Ser168Leu | p.S168L | protein_coding | tolerated(0.47) | benign(0.036) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
TSEN34 | SNV | Missense_Mutation | novel | c.363N>T | p.Glu121Asp | p.E121D | protein_coding | deleterious(0.01) | benign(0.268) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |